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An effective vaccine for hepatitis C virus (HCV) is a major unmet need, and it requires an 27 
antigen that elicits immune responses to key conserved epitopes. Based on structures of 28 
antibodies targeting HCV envelope glycoprotein E2, we designed immunogens to modulate the 29 
structure and dynamics of E2 and favor induction of bNAbs in the context of a vaccine. These 30 
designs include a point mutation in a key conserved antigenic site to stabilize its conformation, 31 
as well as redesigns of an immunogenic region to add a new N-glycosylation site and mask it 32 
from antibody binding. Designs were experimentally characterized for binding to a panel of 33 
human monoclonal antibodies (HMAbs) and the coreceptor CD81 to confirm preservation of 34 
epitope structure and preferred antigenicity profile. Selected E2 designs were tested for 35 
immunogenicity in mice, with and without hypervariable region 1, which is an immunogenic 36 
region associated with viral escape. One of these designs showed improvement in polyclonal 37 
immune serum binding to HCV pseudoparticles and neutralization of isolates associated with 38 
antibody resistance. These results indicate that antigen optimization through structure-based 39 
design of the envelope glycoproteins is a promising route to an effective vaccine for HCV.  40 
 41 




Hepatitis C virus infects approximately 1% of the world’s population, and no vaccine is currently 44 
available. Due to the high variability of HCV and its ability to actively escape the immune 45 
response, a goal of HCV vaccine design is to induce neutralizing antibodies that target conserved 46 
epitopes. Here we performed structure-based design of several epitopes of the HCV E2 envelope 47 
glycoprotein to engineer its antigenic properties. Designs were tested in vitro and in vivo, 48 
demonstrating alteration of the E2 antigenic profile in several cases, and one design led to 49 
improvement of cross-neutralization of heterologous viruses. This represents a proof of concept 50 
that rational engineering of HCV envelope glycoproteins can be used to modulate E2 51 
antigenicity and optimize a vaccine for this challenging viral target.  52 





Hepatitis C virus (HCV) infection is a major global disease burden, with 71 million individuals, 56 
or approximately 1% of the global population, chronically infected worldwide, and 1.75 million 57 
new infections per year (1). Chronic HCV infection can lead to cirrhosis and hepatocellular 58 
carcinoma, the leading cause of liver cancer, and in the United States HCV was found to surpass 59 
HIV and 59 other infectious conditions as a cause of death (2). While the development of direct-60 
acting antivirals has improved treatment options considerably, several factors impede the 61 
effective use of antiviral treatment such as the high cost of antivirals, viral resistance, occurrence 62 
of reinfections after treatment cessation, and lack of awareness of infection in many individuals 63 
since HCV infection is considered a silent epidemic. Therefore, development of an effective 64 
preventative vaccine for HCV is necessary to reduce the burden of infection and transmission, 65 
and for global elimination of HCV (3). 66 
 67 
Despite decades of research resulting in several HCV vaccine candidates tested in vivo and in 68 
clinical trials (4, 5), no approved HCV vaccine is available. There are a number of barriers to the 69 
development of an effective HCV vaccine, including the high mutation rate of the virus which 70 
leads to viral quasi-species in individuals and permits active evasion of T cell and B cell 71 
responses (6). Escape from the antibody response by HCV includes mutations in the envelope 72 
glycoproteins, as observed in vivo in humanized mice (7), studies in chimpanzee models (8), and 73 
through analysis of viral isolates from human chronic infection (9). This was also clearly 74 
demonstrated during clinical trials of a monoclonal antibody, HCV1, which in spite of its 75 
targeting a conserved epitope on the viral envelope, failed to eliminate the virus, as viral variants 76 
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with epitope mutations emerged under immune pressure and dominated the rebounding viral 77 
populations in all treated individuals (10, 11).  78 
 79 
There have been a number of successful structure-based vaccine designs for variable viruses 80 
such as influenza (12, 13), HIV (14, 15), and RSV (16, 17) where rationally designed 81 
immunogens optimize presentation of key conserved epitopes, mask sites using N-glycans, or 82 
stabilize conformations or assembly of the envelope glycoproteins. Recent studies have reported 83 
use of several of these strategies in the context of HCV glycoproteins, including removal or 84 
modification of N-glycans to improve epitope accessibility (18, 19), removal of hypervariable 85 
regions (18, 20, 21), or presentation of key conserved epitopes on scaffolds (22, 23). However, 86 
such studies have been relatively limited compared with other viruses, in terms of design 87 
strategies employed and number of designs tested, and immunogenicity studies have not shown 88 
convincing improvement of glycoprotein designs over native glycoproteins in terms of 89 
neutralization potency or breadth (18, 21), with the possible exception of an HVR-deleted high 90 
molecular weight form of the E2 glycoprotein that was tested in guinea pigs (20).  91 
 92 
Here we report the generation, characterization, and in vivo immunogenicity of novel structure-93 
based designs of the HCV E2 glycoprotein, which is the primary target of the antibody response 94 
to HCV and a major vaccine target. Designs were focused on antigenic domain D, which is a 95 
key region of E2 targeted by broadly neutralizing antibodies (bNAbs) that are resistant to viral 96 
escape (24), as well as antigenic domain A, which is targeted by non-neutralizing antibodies 97 
(25, 26). Based on the intrinsic flexibility of the neutralizing face of E2 (27), which includes 98 
antigenic domain D, and on the locations of bNAb epitopes to this domain (24), we identified a 99 
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structure-based design substitution to reduce the mobility of that region and preferentially form 100 
the bnAb-bound conformation. We also tested several substitutions to hyperglycosylate and 101 
mask antigenic domain A located in a unique region on the back layer of E2, as determined by 102 
fine epitope mapping (28), which represents an approach that has been applied to mask epitopes 103 
in influenza (29) and HIV (30) glycoproteins. Designs were tested for antigenicity using a panel 104 
of monoclonal antibodies (mAbs), and selected designs were tested individually and as 105 
combinations for in vivo immunogenicity. Assessment of immunized sera revealed that certain 106 
E2 designs yielded improvements in serum binding to recombinant HCV particles, as well as 107 
viral cross-neutralization, while maintaining serum binding to soluble E2 glycoprotein and key 108 
epitopes. This provides a proof-of-concept that rational design of HCV glycoproteins can lead 109 
to improvements in immunogenicity and neutralization breadth. 110 
 111 
Results 112 
Structure-based design of E2  113 
We utilized two approaches to design variants of the E2 glycoprotein to improve its antigenicity 114 
and immunogenicity (Figure 1). For one approach, we used the previously reported structure of 115 
the affinity matured bnAb HC84.26.5D bound to its epitope from E2 antigenic domain D (31) 116 
(PDB code 4Z0X), which shows the same epitope conformation observed in the context of other 117 
domain D human monoclonal antibodies (HMAbs) targeting this site (32). Analysis of this 118 
epitope structure for potential proline residue substitutions to stabilize its HMAb-bound 119 
conformation identified several candidate sites (Figure 1A, Table 1). We selected one of these 120 
substitutions, H445P, that is adjacent to core contact residues for domain D located at aa 442-443 121 
(32) for subsequent experimental characterization, due to its position in a region with no 122 
secondary structure, and location between residues Y443 and K446 which both make key 123 
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antibody contacts in domain D antibody complex structures (31, 32). This also represents a 124 
distinct region of the epitope from a substitution that we previously described and tested (A439P) 125 
(28).  126 
 127 
Another design approach, hyperglycosylation, was utilized to mask antigenic domain A, which is 128 
an immunogenic region on the back layer of E2 associated with non-neutralizing antibodies (25, 129 
26, 28). Other antibodies with some binding determinants mapped to this region, including 130 
HMAbs AR1A and HEPC46, exhibit limited or weak neutralization (33). NxS (Asparagine-X-131 
Serine) and NxT (Asparagine-X-Threonine) N-glycan sequon substitutions were modeled in 132 
Rosetta at solvent-exposed E2 positions in antigenic domain A (Figure 1B, Table 2), followed 133 
by visual inspection of the modeled E2 mutant structures to confirm exposure of the mutant 134 
asparagine residues. This analysis suggested that designs with N-glycans at residues 627 135 
(F627N-V629T), 628 (K628N-R630S), 630 (R630N-Y632T), and 632 (Y632N-G634S) 136 
warranted further investigation for effects on antigenicity. 137 
 138 
Initial screening of mutant antigenicity using ELISA 139 
We first screened the structure-based designs described above to assess their effects on E2 140 
glycoprotein antigenicity, to confirm that designs preserved the structure of key E2 epitopes, 141 
and to disrupt non-neutralizing antigenic domain A HMAb binding in the case of the N-glycan 142 
designs. These designs were cloned in E1E2 and assessed using ELISA with a panel of 143 
representative HMAbs to antigenic domains A-E (Figure 2). Only two HMAb concentrations 144 
were tested in this assay, in order to detect major disruptions to HMAb binding, or lack thereof, 145 
rather than quantitative measurements. The results indicate that mutant H445P maintained 146 
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approximately wild-type levels of binding to antibodies, while truncations of HVR1 had varying 147 
effects. Binding of domain E HMAb HC33.4, and to a lesser extent HC33.1, was negatively 148 
affected by truncation of all of HVR1 (residues 384-410 removed; referred to here as 149 
ΔHVR1411), whereas a more limited HVR1 truncation (residues 384-407 removed; referred to 150 
here as ΔHVR1) largely restored binding of those bNAbs. The design of ΔHVR1 was based on 151 
the observation that residue 408 located within HVR1 affected the binding of HC33.4 but not 152 
HC33.1 (34). Likewise, designed N-glycan substitutions showed varying effects on antigenicity, 153 
with pronounced reduction of binding for several bNAbs for F627NT (F627N-V629T) and 154 
R630NT (R630N-Y632T), while K628NS (K628N-R630S) did not exhibit ablation of domain 155 
A antibody binding. In contrast, Y632NS (Y632N-G634S) disrupted binding for both tested 156 
domain A HMAbs, with limited loss of binding for other HMAbs. Based on this antigenic 157 
characterization, designs H445P, ΔHVR1, and Y632NS were selected for further testing. 158 
 159 
Biophysical and antigenic characterization of E2 designs 160 
The two candidate structure-based E2 designs H445P, Y632NS, as well as ΔHVR1, were 161 
expressed and purified as monomeric soluble E2 (sE2) glycoproteins and tested for 162 
thermostability and binding affinity to a panel of HMAbs, as well as the CD81 receptor (Table 163 
3). Pairwise combinations of these designs, and a “Triple” design with all three modifications, 164 
were also expressed and tested. As noted previously by others (27), wild-type sE2 was found to 165 
exhibit high thermostability (Tm = 84.5 C in Table 3). All designs likewise showed high 166 
thermostability, with only minor reductions in Tm, with the exception of combined Triple which 167 




To assess antigenicity of glycoprotein designs, solution binding affinity measurements were 170 
performed with Octet using HMAbs that target E2 antigenic domains A, B, D, and E, with two 171 
antibodies per domain, as well as the receptor CD81 (Table 3). These antibodies have been 172 
previously characterized using multiple global alanine scanning studies (28, 35) (CBH-4G, 173 
CBH-4D, HC33.1, AR3A, HC33.1), and X-ray structural characterization studies (AR3A, 174 
HEPC74, HC84.1, HC33.1, HCV1) (32, 36-39). The HC84.26.WH.5DL is an affinity matured 175 
clone of the parental HC84.26 antibody with improved affinity and neutralization breadth over 176 
the parental antibody (31). The binding site of CD81 has been mapped to E2 residues in 177 
antigenic domains B, D, and E (35), thus CD81 binding provides additional assessment of 178 
antigenicity of that E2 supersite (6). Binding experiments with this panel showed nanomolar 179 
binding affinities to wild-type sE2, which were largely maintained for sE2 designs. A 10-fold 180 
increase in binding affinity of sE2 design H445P for domain D HMAb HC84.26.WH.5DL was 181 
observed, showing that this design, located within antigenic domain D, not only maintained 182 
affinity, but improved engagement in that case; a steady-state binding fit for that interaction is 183 
shown in Figure 3A. However, this effect was not observed for combinations of designs 184 
including H445P, suggesting possible interplay between designed sites. As expected, domain A 185 
hyperglycosylation designs Y632NS, ΔHVR1-Y632NS, and Triple (ΔHVR1-H445P-Y632NS) 186 
showed loss of binding (>5-fold for each) to antigenic domain A HMAb CBH-4G (Y632NS-187 
CBH-4G binding measurement is shown in Figure 3B), though we did not observe disruption of 188 
binding to CBH-4D. Additionally, design ΔHVR1-Y632NS showed moderate (6-fold) loss of 189 
CD81 binding, which was not the case for other designs. As domain A HMAbs have distinct, 190 
albeit similar, binding determinants on E2 (28), differential effects on domain A antibody 191 
binding by Y632NS variants reflect likely differences in HMAb docking footprints on E2. 192 
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Measurements of glycan occupancy at residue 632 using mass spectroscopy showed partial 193 
levels of glycosylation at that site for Y632NS and combinations (Table 4), which may be 194 
responsible for incomplete binding ablation to the tested antigenic domain A HMAbs. As alanine 195 
substitution at Y632 was previously found to disrupt binding of domain A antibodies (28), it is 196 
possible that the Y632N amino acid substitution in the Y632NS may be responsible, in addition 197 
to partial N-glycosylation, for effects on domain A antibody binding. Regardless, these results 198 
suggest at least partial binding disruption and N-glycan masking of this region, supporting 199 
testing of those designs as immunogens in vivo. 200 
 201 
In vivo immunogenicity of E2 designs 202 
Following confirmation of antigenicity, E2 designs were tested in vivo for immunogenicity, to 203 
assess elicitation of antibodies that demonstrate potency and neutralization breadth. CD1 mice (6 204 
per group) were immunized with H77C sE2 and designs, employing Day 0 prime and followed 205 
by three biweekly boosts. Sera were obtained at Day 56 after initial injection (two weeks after 206 
the final boost) and tested for binding to H77C sE2 and key conserved epitopes (AS412/Domain 207 
E, AS434/Domain D) (Figure 4). Peptide epitopes were confirmed for expected monoclonal 208 
antibody specificity using ELISA (Figure 4B). Endpoint titers demonstrated that sera from mice 209 
immunized with E2 designs maintained recognition of sE2 and tested epitopes. Intra-group 210 
variability resulted in lack of statistically significant differences in serum binding between 211 
immunized groups, however mean titers from ΔΗVR1 group were moderately lower than the 212 
wild-type sE2 group, and other mutants yielded moderately higher serum binding to the tested 213 
epitopes. Notably, design H445P elicited antibodies that robustly cross-reacted with the wild 214 
type AS434/Domain D epitope. To assess differential binding to conformational epitopes on E2, 215 
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serum binding competition with selected HMAbs was performed (Figure 5). The observation of 216 
competition in the majority of antisera suggests that elicited antibodies to domain D are to native 217 
conformational epitopes, although there were no major differences between immunized groups. 218 
Likewise, no substantial differences in serum competition for binding to antigenic domains A or 219 
B were detected among immunized groups. 220 
 221 
Serum binding to HCV E1E2 and HCV pseudoparticles 222 
For further analysis of immunized serum binding, we tested binding to concentrated recombinant 223 
H77C E1E2 and HCV pseudoparticles from H77C and two heterologous genotypes (Figure 6, 224 
Table 5). While binding to H77 E1E2 resembled binding to H77 sE2, with no apparent 225 
difference between immunized groups, we observed notable differences in binding to HCVpps 226 
representing H77C, UKNP1.18.1, and J6 for H445P-immunized mice versus mice immunized 227 
with wild-type sE2. The difference between J6 HCVpp binding from H445P-immunized mice 228 
versus sE2-immunized mice was highly significant (p  0.0001, Kruskal-Wallis test). To confirm 229 
this difference in HCVpp binding between sE2 and H445P immunized groups, given the 230 
relatively low levels of overall titers, H77C HCVpps were concentrated and tested in ELISA for 231 
binding to pooled sera from sE2 and H445P immunized mice. This confirmed differences 232 
between immunized groups for sera from Day 56, as well as Day 42, which corresponds to three 233 
rather than four immunizations (Figure 7). To demonstrate native-like E2 and E1E2 assembly of 234 
the HCVpps in the context of the ELISA assay, concentrated HCVpps showed binding to 235 
monoclonal antibodies that target linear and conformational epitopes on E2 (HCV1, 236 
HC84.26.WH.5DL, AR3A) and conformational epitopes on E1E2 (AR4A, AR5A), and did not 237 
interact with negative control antibody (CA45) (Figure 8). The molecular basis for the 238 
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differential serum reactivity when using HCVpp versus purified recombinant E1E2 in ELISA is 239 
unclear, particularly given that sE2 was used as an immunogen, yet these results collectively 240 
provide evidence that H445P may improve targeting of conserved glycoprotein epitopes on the 241 
intact HCV virion.  242 
 243 
Homologous and heterologous serum neutralization 244 
To assess effects of antibody neutralization potency and breadth from E2 designs, we tested 245 
serum neutralization of HCVpp representing homologous H77C and six heterologous isolates 246 
(Figure 9). The heterologous isolates collectively diverge substantially in sequence from H77C 247 
and represent neutralization phenotypes ranging from moderately to highly resistant (Table 5), 248 
with the latter represented by three of the most resistant tested HCVpp from a previous study that 249 
performed characterization with a panel of neutralizing monoclonal antibodies (40) (UKNP2.4.1, 250 
UKNP4.1.1, UKNP1.18.1). As we found previously with immunization of H77C-based sE2 (19), 251 
there was relatively large intra-group variability in neutralization of H77C, and no statistically 252 
significant differences between groups were observed. However, ID50 values for individual mice 253 
varied less within immunized groups for heterologous isolates. Comparison between groups 254 
immunized with sE2 designs and wild-type sE2 showed significantly higher neutralization in 255 
some cases. Notably, two resistant isolates had significantly higher neutralization for H445P-256 
immunized sera than wild-type sE2-immunized sera (UKNP1.18.1, J6). 257 
 258 
Analysis of correlates of immunogenicity and antigenicity 259 
Based on our in vitro and in vivo measurements, we assessed correlations between serum 260 
neutralization of different genotypes, serum antigen binding, and antigenicity (Figure 10). First, 261 
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we performed correlations between immunogenicity measurements for individual murine sera, 262 
corresponding to 42 points per dataset. Measurements of HCVpp serum binding were not 263 
included in this analysis, due to low and unquantifiable binding measurements for multiple mice 264 
for those assays (Figure 6B-D). Top correlations between immunogenicity measurements 265 
(Figure 10A) include serum binding values (EC50) to sE2 versus E1E2 (r = 0.84), J6 266 
neutralization (ID50) versus UKNP1.18.1 neutralization (r = 0.66), and UKNP2.4.1 267 
neutralization versus UKNP1.18.1 neutralization (r = 0.51), all of which were highly significant 268 
(p  0.001). The latter two correlations highlight shared patterns of neutralization of HCVpp with 269 
resistant phenotypes; a plot of UKNP2.4.1 HCVpp ID50 values versus UKNP1.18.1 HCVpp 270 
ID50 values is shown in Figure 10B.  271 
 To assess possible associations between antigenicity and immunogenicity, we calculated 272 
correlations between measured binding affinity values for HMAbs and group immunogenicity 273 
measurements (endpoint titer or HCVpp ID50). Such analysis has been used by others with other 274 
viral antigen designs to examine antigenic properties associated with immunogenicity (16). Top 275 
correlations based on significance (p-value) are shown in Figure 10C. As with the individual 276 
mouse correlation analysis noted above, HCVpp endpoint titers were excluded from this analysis 277 
due to insignificant binding values in several groups. As expected due to limited number of data 278 
points and limited overall variability in binding affinity measurements (Table 3), few 279 
correlations between antigenic and immunogenic parameters were highly significant, though 280 
binding of domain D HMAb HC84.26.WH.5DL was highly correlated with neutralization of J6 281 
HCVpp (r = 0.97, p = 0.0003), as well as neutralization of UKNP1.18.1 HCVpp (r = 0.88, p = 282 
0.008), while anticorrelations were detected for other antibody binding measurements (HEPC74 283 
and HCV1) and HCVpp group neutralization values, at lower significance levels. The high 284 
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correlations involving HMAb HC84.26.WH.5DL are not unexpected, based on the higher HMAb 285 
binding affinity to the H445P sE2 antigen and higher nAb responses induced by H445P; Figure 286 
10D compares UKNP1.18.1 neutralization with HC84.26.WH.5DL binding, where the point 287 
corresponding to H445P is in the upper right.  288 
 289 
Discussion 290 
In this study, we applied a variety of rational design approaches to engineer the HCV E2 291 
glycoprotein to improve its antigenicity and immunogenicity. One of these approaches, removal 292 
of HVR1 (ΔHVR1), has been tested in several recent immunogenicity studies, in the context of 293 
E2 (18, 20, 23) and E1E2 (21). In this study, we tested the E2 ΔHVR1 mutant with residues 384-294 
407 removed, which retains residues 408-661 of E2; this is a more conservative truncation than 295 
previously tested ΔHVR1 mutants, in order to retain residue 408 which is binding determinant 296 
for the HC33.4 HMAb and others (28, 34).  Here we found this mutant to not be advantageous 297 
from an immunogenicity standpoint, which is in agreement with most other previous 298 
immunogenicity studies testing ΔHVR1 mutants (18, 21, 23). Although HVR1 is an 299 
immunogenic epitope, its removal from recombinant E2 glycoprotein does not appear to increase 300 
homologous or heterologous nAb titers, with the latter suggesting that the level of antibodies 301 
targeting conserved nAb epitopes did not increase upon HVR1 removal. Based largely on studies 302 
of engineered viruses in cell culture, as summarized in a recent review (41), removal of HVR1 is 303 
associated with increased nAb sensitivity and CD81 receptor binding, while a recent study has 304 
indicated that HVR1 may modulate viral dynamics and open and closed conformations during 305 
envelope breathing (42). Despite its importance in the context of the virion and its dynamics, its 306 
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removal appears to have a neutral or minimal effect on the immunogenicity of recombinant 307 
envelope glycoproteins.  308 
 309 
Another design strategy tested in this study was hyperglycosylation, through structure-based 310 
addition of N-glycan sequons to mask antigenic domain A, which is associated with non-311 
neutralizing antibodies (25, 26, 28, 43). The concept of down-modulating immunity to this 312 
region was based on the observation that this region is highly immunogenic and may divert 313 
antibody responses to bNAb epitopes of lower immunogenicity. Through the efforts of isolating 314 
bNAbs to distinct regions on E2 from multiple HCV infected individuals, non-neutralizing 315 
antibodies to domain A are consistently identified (personal communication, S. Foung). This 316 
strategy has been successfully employed for other glycoprotein immunogens, including for HIV 317 
Env SOSIP trimers, where the immunogenic V3 loop was masked with designed N-glycans (30). 318 
Surprisingly, some of the designs in this study exhibited an impact on recognition by antibodies 319 
targeting antigenic domain D on the front layer of E2, suggesting a possible interplay between 320 
the front and back layers of E2, as proposed previously based on global alanine scanning 321 
mutagenesis (35). As observed by Ringe et al. in the context of HIV Env (30), the designed E2 322 
N-glycan variant tested for immunogenicity in this study (Y632NS) did not show improvements 323 
in nAb elicitation. However, its combination with ΔHVR1 did lead to modest improvement in 324 
nAb titers against one resistant isolate (UKNP2.4.1; p-value < 0.05), compared with wild-type 325 
sE2. Previously we used insect cell expression to alter the N-glycan profile of sE2 versus 326 
mammalian cell expressed sE2 (19), and others have recently tested immunogenicity for glycan-327 
deleted E2 and E1E2 variants (18); in neither case was a significant improvement in homologous 328 
and heterologous nAb responses observed for immunogens with altered glycans. Collectively, 329 
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these results suggest that glycoengineering of E2 or E1E2 represents a more challenging, and 330 
possibly less beneficial, avenue for HCV immunogen design, however a report of success by 331 
others through insect cell expressed sE2 indicates that altered glycosylation may help in some 332 
instances (44).  333 
 334 
The designed substitution H445P, which was generated to preferentially adopt the bnAb-bound 335 
form in a portion of E2 antigenic domain D that exhibits structural variability (31), showed the 336 
greatest level of success, both with regard to improvements in serum binding to homologous and 337 
heterologous HCVpp, as well as HCVpp neutralization of heterologous HCVpp. This design lies 338 
within a supersite of E2 associated with many broadly neutralizing antibodies (5, 6, 45, 46), and 339 
through biophysical characterization and molecular dynamics simulation experiments, others 340 
have found that this region is likely quite flexible (27, 47), providing a rationale for stabilizing 341 
key residues to engage and elicit bNAbs. Interestingly, a residue adjacent to the site of this 342 
design appears to be functionally important, with the Q444R substitution restoring viral 343 
infectivity in the context of an HCVpp with a domain E “glycan shift” substitution, N417S (8). 344 
The design strategy of utilizing proline residue substitutions to stabilize conformations of viral 345 
glycoproteins has been successful for HIV Env (48), respiratory syncytial virus (RSV) F (49), 346 
MERS coronavirus spike (50), and recently, the novel coronavirus (SARS-CoV-2) spike (51). 347 
The data from this study suggest that this approach is also useful in the context of HCV E2, and 348 
possibly E1E2.  349 
 350 
This study provides a proof-of-concept for computational structure-based design of the HCV E2 351 
glycoprotein to modulate its antigenicity and immunogenicity. Future studies with the H445P 352 
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design include testing of its antigenicity and immunogenicity in the context of HCV E1E2, 353 
testing immunogenicity in other animal models, as well as confirmation of its impact on E2 354 
structure through high resolution X-ray structural characterization and additional biophysical 355 
characterization. Confirmation of improved elicitation of neutralizing antibodies with a cell-356 
culture based HCV assay (HCVcc), versus the pseudoparticle-based assay (HCVpp) used in this 357 
study, can provide further insight into the impact of these and other HCV envelope glycoprotein 358 
variants. However, the employment of HCVpp does permit a greater ease in testing against 359 
clinical isolates. Furthermore, additional designed proline substitutions in this flexible E2 360 
“neutralizing face” supersite may confer greater improvements in homologous and heterologous 361 
nAb elicitation; these can be generated using structure-based design, or with a semi-rational 362 
library-based approach, as was used to scan a large set of proline substitutions for HIV Env (52). 363 
This study provides a promising design candidate for follow-up studies, underscoring the value 364 
of the set of previously determined, though somewhat limited, set of E2-bnAb complex 365 
structures. Prospective elucidation of the structure of E2 in complex with additional bNAbs, as 366 
well as characterization of the E1E2 complex structure, will facilitate future structure-based 367 
design studies to engineer and optimize immunogens for an effective HCV vaccine.  368 
 369 
Materials and Methods 370 
Computational modeling and design 371 
Proline substitution designs to stabilize epitopes were modeled as previously described for 372 
design of T cell receptor binding loops (53), using a Ramachandran plot server to assess epitope 373 
residue backbone conformations for proline and pre-proline conformational similarities 374 
(http://zlab.bu.edu/rama)(54), as well as explicit modeling of energetic effects of proline 375 
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substitutions using the point mutagenesis mode of Rosetta version 2.3 (55). N-glycan sequon 376 
substitutions (NxS, NxT) were modeled using Rosetta (55), followed by modeling of the N-377 
glycan structure using the Glyprot web server (56). Assessment of residue side chain accessible 378 
surface areas was performed using NACCESS (57) with default parameters. 379 
 380 
Protein and antibody expression and purification 381 
Expression and purification of recombinant soluble HCV E2 (sE2) and designs was performed as 382 
previously described (19). Briefly, the sequence from isolate H77C (GenBank accession number 383 
AF011751; residues 384–661) was cloned into the pSecTag2 vector (Invitrogen), transfected 384 
with 293fectin into FreeStyle HEK293-F cells (Invitrogen), and purified from culture 385 
supernatants by sequential HisTrap Ni
2+
-NTA and Superdex 200 columns (GE Healthcare). For 386 
recombinant HCV E1E2 expression, the H77C E1E2 glycoprotein coding region (GenBank 387 
accession number AF011751) was synthesized with a modified tPA signal peptide (58) at the N-388 
terminus and cloned into the vector pcDNA3.1+ at the cloning sites of KpnI/NotI (GenScript). 389 
Expi293 cells (Thermo Fisher) were used to express the E1E2 glycoprotein complex. In brief, the 390 
Expi293 cells were grown in Expi293 medium (ThermoFisher) at 37°C, 125 rpm, 8% CO2 and 391 
80% humidity in Erlenmeyer sterile polycarbonate flasks (VWR). The day before the 392 
transfection, 2.0 × 10
6
 viable cells/ml was seeded in a flask and the manufacturer’s protocol 393 
(A14524, ThermoFisher) was followed for transfection performance. After 72 hours post-394 
transfection, the cell pellets were harvested by centrifuging cells at 3,000 x g for 5 min and the 395 
cell pellet were then stored at -80 °C for further processing. Recombinant E1E2 was extracted 396 
from cell membranes using 1% NP-9 and purified via sequential Fractogel EMD TMAE 397 
(Millipore), Fractogel EMD SO3
-
 (Millipore). HC84.26 immunoaffinity, and Galanthus Nivalis 398 
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Lectin (GNL, Vector Laboratories) affinity chromatography. Monoclonal antibody HCV1 was 399 
provided by Dr. Yang Wang (MassBiologics, University of Massachusetts Medical School), and 400 
monoclonal antibodies AR3A, AR4A, and AR5A were provided by Dr. Mansun Law (Scripps 401 
Research Institute). All other monoclonal antibodies used in ELISA and binding studies were 402 
produced as previously described (24, 25, 59). A clone for mammalian expression of CD81 large 403 
extracellular loop (LEL), containing N-terminal tPA signal sequence and C-terminal twin Strep 404 
tag, was provided by Joe Grove (University College London). CD81-LEL was expressed through 405 
transiently transfection in Expi293F cells (ThermoFisher) and purified from supernatant with a 406 
Gravity Flow Strep-Tactin Superflow high capacity column (IBA Lifesciences). Purified CD81-407 
LEL was polished by size exclusion chromatography (SEC) with a Superdex 75 10/300 GL 408 
column (GE Healthcare) on an Akta FPLC (GE Healthcare). 409 
 410 
ELISA antigenic characterization and competition assays 411 
Cloning and characterization of E2 mutant antigenicity using ELISA was performed as described 412 
previously (28). Mutants were constructed in plasmids carrying the 1a H77C E1E2 coding 413 
sequence (GenBank accession number AF009606), as described previously (60). All the 414 
mutations were confirmed by DNA sequence analysis (Elim Biopharmaceuticals, Inc., Hayward, 415 
CA) for the desired mutations and for absence of unexpected residue changes in the full-length 416 
E1E2-encoding sequence. The resulting plasmids were transfected into HEK 293T cells for 417 
transient protein expression using the calcium-phosphate method. Individual E2 protein 418 
expression was normalized by binding of CBH-17, an HCV E2 HMAb to a linear epitope (61). 419 
Serum samples at specified dilutions were tested for their ability to block the binding of selected 420 
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HCV HMAbs-conjugated with biotin in a GNA-captured E1E2 glycoproteins ELISA, as 421 
described (24). Data are shown as mean values of two experiments performed in triplicate. 422 
 423 
Biolayer interferometry 424 
The interaction of recombinant sE2 glycoproteins with CD81 and HMAbs in was measured 425 
using an Octet RED96 instrument and Ni
2+
-NTA biosensors (Pall ForteBio). The biosensors 426 
were loaded with 5 g/mL of purified His6-tagged wild-type or mutant sE2 for 600 seconds. 427 
Association for 300 sec followed by dissociation for 300 seconds against a 2-fold concentration 428 
dilution series of each antibody was performed. Data analysis was performed using Octet Data 429 
Analysis 10.0 software and utilized reference subtraction at 0 nM antibody concentration, 430 
alignment to the baseline, interstep correction to the dissociation step, and Savitzky-Golay 431 
fitting. Curves were globally fitted based on association and dissociation to obtain KD values.  432 
 433 
Differential scanning calorimetry 434 
Thermal melting curves for monomeric E2 proteins were acquired using a MicroCal PEAQ-DSC 435 
automated system (Malvern Panalytical). Purified monomeric E2 proteins were dialyzed into 436 
PBS prior to analysis and the dialysis buffer was used as the reference in the experiments. 437 
Samples were diluted to 10 M in PBS prior to analysis. Thermal melting was probed at a scan 438 
rate of 90 °C∙h-1 over a temperature range of 25 to 115 °C. All data analyses including estimation 439 
of the melting temperature were performed using standard protocols that are included with the 440 
PEAQ-DSC software. 441 
 442 
Mass spectrometry 443 
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Digestion was performed on 40 μg each of HEK293-derived sE2 glycan sequon substitutions by 444 
denaturing using 6 M guanidine HCl, 1 mM EDTA in 0.1 M Tris, pH 7.8, reduced with a final 445 
concentration of 20 mM DTT (65 °C for 90 min), and alkylated at a final concentration of 50 446 
mM iodoacetamide (room temperature for 30 min). Samples were then buffer exchanged into 1 447 
M urea in 0.1 M Tris, pH 7.8 for digestion. Sequential digestion was performed using trypsin 448 
(1/50 enzyme/protein ratio, w/w) for 18 hours at 37 °C, followed by chymotrypsin (1/20 449 
enzyme:protein, w/w) overnight at room temperature. Samples were then absorbed onto Sep-Pak 450 
tC18 columns to remove proteolytic digestion buffer, eluted with 50% acetonitrile/0.1% 451 
trifluoroacetic acid (TFA) buffer and concentrated to dryness in a centrifugal vacuum 452 
concentrator. The samples were then resuspended in 50 mM Sodium acetate pH 4.5 and 453 
incubated with Endo F1, Endo F2, and Endo F3 (QA Bio) at 37 °C for 72 hours to remove 454 
complex glycans. LC-UV-MS analyses were performed using an UltiMate 3000 LC system 455 
coupled to an LTQ Orbitrap Discovery equipped with a heated electrospray ionization (HESI) 456 
source and operated in a top 5 dynamic exclusion mode. A volume of 25 l (representing 10 g 457 
of digested protein) of sample was loaded via the autosampler onto a C18 peptide column 458 
(AdvanceBio Peptide 2.7 um, 2.1 x 150 mm, Agilent part number 653750-902) enclosed in a 459 
thermostatted column oven set to 50 °C. Samples were held at 4°C while queued for injection. 460 
The chromatographic gradient was conducted as described previously (19). Identification of 461 
glycosylated peptides containing the glycan sequon substitution was performed using Byonic 462 
software and extracted ion chromatograms used for estimating the relative abundance of the 463 
glycosylated peptides in Byologic software (Protein Metrics). 464 
 465 
Animal immunization 466 
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CD-1 mice were purchased from Charles River Laboratories. Prior to immunization, sE2 467 
antigens were formulated with polyphosphazene adjuvant.  468 
Poly[di(carboxylatophenoxy)phosphazene], PCPP (molecular weight 800,000 Da) (62) was 469 
dissolved in PBS (pH 7.4) and mixed with sE2 antigen solution at 1:1 (prime) or 1:5 (w/w) 470 
(boost immunization) antigen:adjuvant ratio to provide for 50 mcg PCPP dose per animal. The 471 
absence of aggregation in adjuvanted formulations was confirmed by dynamic light scattering 472 
(DLS): single peak, z-average hydrodynamic diameter – 60 nm. The formation of sE2 antigen – 473 
PCPP complex was proven by asymmetric flow field flow fractionation (AF4) as described 474 
previously (63). On scheduled vaccination days, groups of 6 female mice, age 7-9 weeks, were 475 
injected via the intraperitoneal (IP) route with a 50 µg sE2 prime (day 0) and boosted with 10 µg 476 
sE2 on days 7, 14, 28, and 42. Blood samples were collected prior to each injection with a 477 
terminal bleed on day 56. The collected samples were processed for serum by centrifugation and 478 
stored at -80°C until analysis was performed. 479 
 480 
Serum peptide and protein ELISA 481 
Domain-specific serum binding was tested using ELISA with C-terminal biotinylated peptides 482 
from H77C AS412 (aa 410-425; sequence NIQLINTNGSWHINST) and AS434 (aa 434-446; 483 
sequence NTGWLAGLFYQHK), using 2 μg/ml coating concentration. Recombinant sE2 and 484 
E1E2 proteins were captured onto GNA-coated microtiter plates. Endpoint titers were calculated 485 
by curve fitting in GraphPad Prism software, with endpoint OD defined as four times the highest 486 
absorbance value of Day 0 sera. 487 
 488 
HCV pseudoparticle generation 489 
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HCV pseudoparticles (HCVpp) were generated as described previously (19), by co-transfection 490 
of HEK293T cells with the murine leukemia virus (MLV) Gag-Pol packaging vector, luciferase 491 
reporter plasmid, and plasmid expressing HCV E1E2 using Lipofectamine 3000 (Thermo Fisher 492 
Scientific). Envelope-free control (empty plasmid) was used as negative control in all 493 
experiments. Supernatants containing HCVpp were harvested at 48 h and 72 h post-transfection, 494 
and filtered through 0.45 μm pore-sized membranes. Concentrated HCVpp were obtained by 495 
ultracentrifugation of 33 ml of filtered supernatants through a 7 ml 20% sucrose cushion using an 496 
SW 28 Beckman Coulter rotor at 25,000 rpm for 2.5 hours at 4°C, following a previously 497 
reported protocol (26).  498 
 499 
HCVpp serum binding 500 
For measurement of serum binding to HCVpp, 100 µL of 0.45 µm filtered HCVpp isolates were 501 
directly coated onto Nunc-immuno MaxiSorp (Thermo Scientific) microwells overnight at 4°C. 502 
Microwells were washed three times with 300 µL of 1X PBS, 0.05% Tween 20 in between steps. 503 
Wells were blocked with Pierce Protein-Free Blocking buffer (Thermo Scientific) for 1 hour. 504 
Serum sample dilutions made in blocking buffer were added to the microwells and incubated for 505 
1 hour at room temperature. Abs were detected with secondary HRP conjugated goat anti-mouse 506 
IgG H&L (Abcam, ab97023) and developed with TMB substrate solution (Bio-Rad). The 507 
reaction was stopped with 2M sulfuric acid. A Molecular Devices M3 plate reader was used to 508 
measure absorbance at 450 nm. Endpoint titers were calculated by curve fitting in GraphPad 509 
Prism software, with endpoint OD defined as four times the highest absorbance value of Day 0 510 




HCVpp neutralization assays 513 
For infectivity and neutralization testing of HCVpp, 1.5 x 10
4
 Huh7 cells per well were plated in 514 
96-well tissue culture plates (Corning) and incubated overnight at 37 °C. The following day, 515 
HCVpp were mixed with appropriate amounts of antibody and then incubated for 1 h at 37 °C 516 
before adding them to Huh7 cells. After 72 h at 37 °C, either 100 μl Bright-Glo (Promega) was 517 
added to each well and incubated for 2 min or cells were lysed with Cell lysis buffer (Promega 518 
E1500) and placed on a rocker for 15 min. Luciferase activity was then measured in relative light 519 
units (RLUs) using either a SpectraMax M3 microplate reader (Molecular Devices) with 520 
SoftMax Pro6 software (Bright-Glo protocol) or wells were individually injected with 50 μL 521 
luciferase substrate and read using a FLUOstar Omega plate reader (BMG Labtech) with MARS 522 
software. Infection by HCVpp was measured in the presence of anti-E2 MAbs, tested animal 523 
sera, pre-immune animal sera, and non-specific IgG at the same dilution. Each sample was tested 524 
in duplicate or triplicate. Neutralizing activities were reported as 50% inhibitory dilution (ID50) 525 
values and were calculated by nonlinear curve fitting (GraphPad Prism), using lower and upper 526 
bounds (0% and 100% inhibition) as constraints to assist curve fitting. 527 
 528 
Statistical comparisons and correlations 529 
P-values between group endpoint titers and group ID50 values were calculated using Kruskal-530 
Wallis one-way analysis of variance (ANOVA), with Dunn’s multiple comparison test, in 531 
Graphpad Prism software. Pearson correlations and correlation significance p-values were 532 





We thank Joe Grove (University College London) for kindly providing the CD81-LEL 536 
expression plasmid. We also thank Verna Frasca (Malvern Panalytical) for performing and 537 
analyzing the DSC experiments, and Sneha Rangarajan (University of Maryland IBBR) for 538 
useful discussions regarding the antigenic domain D structure. This work was supported in part 539 
by National Institute of Allergy and Infectious Diseases/NIH grants R21-AI126582 (BGP, RAM, 540 
SKHF), R01-AI132213 (BGP, AKA, RAM, TRF, SKHF), and U19-AI123862 (SKHF). 541 
 542 




1. WHO. 2017. Global Hepatitis Report 2017. World Health Organization. 545 
2. Ly KN, Hughes EM, Jiles RB, Holmberg SD. 2016. Rising Mortality Associated With 546 
Hepatitis C Virus in the United States, 2003-2013. Clin Infect Dis 62:1287-8. 547 
3. Cox AL. 2015. MEDICINE. Global control of hepatitis C virus. Science 349:790-1. 548 
4. Walker CM, Grakoui A. 2015. Hepatitis C virus: why do we need a vaccine to prevent a 549 
curable persistent infection? Curr Opin Immunol 35:137-43. 550 
5. Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. 2016. Hepatitis C 551 
virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev 552 
Vaccines doi:10.1080/14760584.2016.1194759:1-10. 553 
6. Pierce BG, Keck ZY, Foung SK. 2016. Viral evasion and challenges of hepatitis C virus 554 
vaccine development. Curr Opin Virol 20:55-63. 555 
7. Prentoe J, Verhoye L, Velazquez Moctezuma R, Buysschaert C, Farhoudi A, Wang R, 556 
Alter H, Meuleman P, Bukh J. 2015. HVR1-mediated antibody evasion of highly 557 
infectious in vivo adapted HCV in humanised mice. Gut doi:10.1136/gutjnl-2015-558 
310300. 559 
8. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, 560 
Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, 561 
Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. 2012. Human Monoclonal 562 
Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS 563 
pathogens 8:e1002895. 564 
9. Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, 565 
Alter H, Rice CM, Foung SK. 2009. Mutations in hepatitis C virus E2 located outside the 566 
CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise 567 
virus infectivity. J Virol 83:6149-60. 568 
10. Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl 569 
M, Pomposelli JJ, Pomfret EA, Florman S, Schilsky M, Broering TJ, Finberg RW, Szabo 570 
G, Zamore PD, Khettry U, Babcock GJ, Ambrosino DM, Leav B, Leney M, Smith HL, 571 
Molrine DC. 2013. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound 572 
following liver transplantation: a randomized controlled study. Am J Transplant 13:1047-573 
54. 574 
11. Babcock GJ, Iyer S, Smith HL, Wang Y, Rowley K, Ambrosino DM, Zamore PD, Pierce 575 
BG, Molrine DC, Weng Z. 2014. High-throughput sequencing analysis of post-liver 576 
transplantation HCV E2 glycoprotein evolution in the presence and absence of 577 
neutralizing monoclonal antibody. PLoS One 9:e100325. 578 
12. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van 579 
Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, 580 
Kukrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, 581 
Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, 582 
Ward AB, Meijberg W, Wilson IA, Radosevic K. 2015. A stable trimeric influenza 583 
hemagglutinin stem as a broadly protective immunogen. Science 349:1301-6. 584 
13. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher 585 
JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao 586 
SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS. 2015. Hemagglutinin-587 
stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21:1065-70. 588 
 
 27 
14. de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien JP, van den 589 
Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer 590 
I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, 591 
Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore 592 
JP, Wilson IA, Ward AB, Sanders RW. 2015. Immunogenicity of Stabilized HIV-1 593 
Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell 163:1702-594 
15. 595 
15. Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A, Cottrell CA, 596 
Havenar-Daughton C, Ozorowski G, Georgeson E, Kalyuzhniy O, Willis JR, Kubitz M, 597 
Adachi Y, Reiss SM, Shin M, de Val N, Ward AB, Crotty S, Burton DR, Schief WR. 598 
2017. Structure-based design of native-like HIV-1 envelope trimers to silence non-599 
neutralizing epitopes and eliminate CD4 binding. Nat Commun 8:1655. 600 
16. Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet 601 
EJ, Tsybovsky Y, Yang Y, Georgiev IS, Guttman M, Lees CR, Pancera M, Sastry M, 602 
Soto C, Stewart-Jones GB, Thomas PV, Van Galen JG, Baxa U, Lee KK, Mascola JR, 603 
Graham BS, Kwong PD. 2016. Iterative structure-based improvement of a fusion-604 
glycoprotein vaccine against RSV. Nat Struct Mol Biol 23:811-20. 605 
17. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti 606 
C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, 607 
Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, 608 
Strong RK, Crowe JE, Jr., Johnson PR, Schief WR. 2014. Proof of principle for epitope-609 
focused vaccine design. Nature 507:201-6. 610 
18. Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Khan AG, Schulze 611 
K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, 612 
Viejo-Borbolla A, Stroh LJ, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, 613 
Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T. 2019. Functional and 614 
immunogenic characterization of diverse HCV glycoprotein E2 variants. J Hepatol 615 
70:593-602. 616 
19. Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, 617 
Garagusi KJ, Tan L, Guest JD, Ball JK, Pierce BG, Mariuzza RA, Foung SKH, Fuerst 618 
TR. 2019. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C 619 
Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells. J Virol 93. 620 
20. Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, 621 
Center RJ, Poumbourios P, Drummer HE. 2017. The core domain of hepatitis C virus 622 
glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology 623 
65:1117-1131. 624 
21. Law JLM, Logan M, Wong J, Kundu J, Hockman D, Landi A, Chen C, Crawford K, 625 
Wininger M, Johnson J, Mesa Prince C, Dudek E, Mehta N, Tyrrell DL, Houghton M. 626 
2018. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a 627 
Recombinant Hepatitis C Virus Vaccine. J Virol 92. 628 
22. He L, Cheng Y, Kong L, Azadnia P, Giang E, Kim J, Wood MR, Wilson IA, Law M, 629 
Zhu J. 2015. Approaching rational epitope vaccine design for hepatitis C virus with meta-630 
server and multivalent scaffolding. Sci Rep 5:12501. 631 
23. Pierce BG, Boucher EN, Piepenbrink KH, Ejemel M, Rapp CA, Thomas WD, Jr., 632 
Sundberg EJ, Weng Z, Wang Y. 2017. Structure-Based Design of Hepatitis C Virus 633 
 
 28 
Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. J Virol 634 
91:e01032-17. 635 
24. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, 636 
Lemon SM, Bukh J, Rey FA, Foung SK. 2012. Human monoclonal antibodies to a novel 637 
cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in 638 
a genotype 2a isolate. PLoS Pathog 8:e1002653. 639 
25. Keck ZY, Op De Beeck A, Hadlock KG, Xia J, Li TK, Dubuisson J, Foung SK. 2004. 640 
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes 641 
with distinct properties and biological functions. J Virol 78:9224-32. 642 
26. Keck ZY, Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J, Foung SK. 2005. Analysis 643 
of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J 644 
Virol 79:13199-208. 645 
27. Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods 646 
VL, Jr., Ward AB, Li S, Wilson IA, Law M. 2016. Structural flexibility at a major 647 
conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A 648 
doi:10.1073/pnas.1609780113. 649 
28. Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, 650 
Mariuzza RA, Foung SKH. 2016. Global mapping of antibody recognition of the 651 
hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc Natl Acad Sci U 652 
S A 113:E6946-E6954. 653 
29. Eggink D, Goff PH, Palese P. 2014. Guiding the immune response against influenza virus 654 
hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular 655 
head domain. J Virol 88:699-704. 656 
30. Ringe RP, Ozorowski G, Rantalainen K, Struwe WB, Matthews K, Torres JL, Yasmeen 657 
A, Cottrell CA, Ketas TJ, LaBranche CC, Montefiori DC, Cupo A, Crispin M, Wilson 658 
IA, Ward AB, Sanders RW, Klasse PJ, Moore JP. 2017. Reducing V3 Antigenicity and 659 
Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. J Virol 91. 660 
31. Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, 661 
Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, 662 
Kneteman NM, Foung SK. 2016. Affinity maturation of a broadly neutralizing human 663 
monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology 664 
64:1922-1933. 665 
32. Krey T, Meola A, Keck ZY, Damier-Piolle L, Foung SK, Rey FA. 2013. Structural basis 666 
of HCV neutralization by human monoclonal antibodies resistant to viral neutralization 667 
escape. PLoS Pathog 9:e1003364. 668 
33. Kinchen VJ, Cox AL, Bailey JR. 2018. Can Broadly Neutralizing Monoclonal Antibodies 669 
Lead to a Hepatitis C Virus Vaccine? Trends Microbiol 26:854-864. 670 
34. Keck ZY, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey FA, Krey T, Diamond MS, 671 
Foung SK. 2016. Antibody Response to Hypervariable Region 1 Interferes with Broadly 672 
Neutralizing Antibodies to Hepatitis C Virus. J Virol 90:3112-22. 673 
35. Gopal R, Jackson K, Tzarum N, Kong L, Ettenger A, Guest J, Pfaff JM, Barnes T, Honda 674 
A, Giang E, Davidson E, Wilson IA, Doranz BJ, Law M. 2017. Probing the antigenicity 675 
of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. 676 
PLoS Pathog 13:e1006735. 677 
 
 29 
36. Tzarum N, Giang E, Kong L, He L, Prentoe J, Augestad E, Hua Y, Castillo S, Lauer GM, 678 
Bukh J, Zhu J, Wilson IA, Law M. 2019. Genetic and structural insights into broad 679 
neutralization of hepatitis C virus by human VH1-69 antibodies. Sci Adv 5:eaav1882. 680 
37. Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Jr., Bailey JR, Bjorkman PJ. 2018. 681 
HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an 682 
E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host Microbe 683 
24:703-716 e3. 684 
38. Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung SK, Mariuzza RA. 2015. 685 
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein 686 
by a broadly neutralizing human antibody. J Biol Chem 290:10117-25. 687 
39. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law M. 2012. 688 
Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody 689 
HCV1. Proceedings of the National Academy of Sciences of the United States of 690 
America 109:9499-504. 691 
40. Urbanowicz RA, McClure CP, Brown RJ, Tsoleridis T, Persson MA, Krey T, Irving WL, 692 
Ball JK, Tarr AW. 2015. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in 693 
Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. 694 
J Virol 90:3288-301. 695 
41. Prentoe J, Bukh J. 2018. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C 696 
Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Front Immunol 697 
9:2146. 698 
42. Prentoe J, Velazquez-Moctezuma R, Augestad EH, Galli A, Wang R, Law M, Alter H, 699 
Bukh J. 2019. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion 700 
neutralization by modulating envelope conformations. Proc Natl Acad Sci U S A 701 
116:10039-10047. 702 
43. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari 703 
FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. 704 
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. 705 
Nat Med 14:25-7. 706 
44. Li D, von Schaewen M, Wang X, Tao W, Zhang Y, Li L, Heller B, Hrebikova G, Deng 707 
Q, Ploss A, Zhong J, Huang Z. 2016. Altered Glycosylation Patterns Increase 708 
Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing 709 
Antibodies Which Confer Protection in Mice. J Virol 90:10486-10498. 710 
45. Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, 711 
Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, Ray SC, 712 
Crowe JE, Jr. 2017. Broadly neutralizing antibodies with few somatic mutations and 713 
hepatitis C virus clearance. JCI Insight 2. 714 
46. Merat SJ, Molenkamp R, Wagner K, Koekkoek SM, van de Berg D, Yasuda E, Bohne M, 715 
Claassen YB, Grady BP, Prins M, Bakker AQ, de Jong MD, Spits H, Schinkel J, 716 
Beaumont T. 2016. Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies 717 
Isolated 25 Years after Spontaneous Clearance. PLoS One 11:e0165047. 718 
47. Stejskal L, Lees WD, Moss DS, Palor M, Bingham RJ, Shepherd AJ, Grove J. 2020. 719 
Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 720 
glycoprotein. PLoS Comput Biol 16:e1007710. 721 
48. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, 722 
de la Pena AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, 723 
 
 30 
Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A next-generation cleaved, soluble 724 
HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly 725 
neutralizing but not non-neutralizing antibodies. PLoS Pathog 9:e1003618. 726 
49. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, 727 
Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JPM. 2015. A 728 
highly stable prefusion RSV F vaccine derived from structural analysis of the fusion 729 
mechanism. Nat Commun 6:8143. 730 
50. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, 731 
Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, 732 
Chappell JD, Graham BS, Ward AB, McLellan JS. 2017. Immunogenicity and structures 733 
of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 734 
114:E7348-E7357. 735 
51. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, 736 
McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion 737 
conformation. Science 367:1260-1263. 738 
52. Sullivan JT, Sulli C, Nilo A, Yasmeen A, Ozorowski G, Sanders RW, Ward AB, Klasse 739 
PJ, Moore JP, Doranz BJ. 2017. High-Throughput Protein Engineering Improves the 740 
Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. J 741 
Virol 91. 742 
53. Pierce BG, Hellman LM, Hossain M, Singh NK, Vander Kooi CW, Weng Z, Baker BM. 743 
2014. Computational design of the affinity and specificity of a therapeutic T cell receptor. 744 
PLoS Comput Biol 10:e1003478. 745 
54. Anderson RJ, Weng Z, Campbell RK, Jiang X. 2005. Main-chain conformational 746 
tendencies of amino acids. Proteins 60:679-89. 747 
55. Kortemme T, Baker D. 2002. A simple physical model for binding energy hot spots in 748 
protein-protein complexes. Proc Natl Acad Sci U S A 99:14116-21. 749 
56. Bohne-Lang A, von der Lieth CW. 2005. GlyProt: in silico glycosylation of proteins. 750 
Nucleic acids research 33:W214-9. 751 
57. Hubbard SJ, Thornton JM. 1993. NACCESS, v2.1.1. Department of Biochemistry and 752 
Molecular Biology, University College London,  753 
58. Wen B, Deng Y, Guan J, Yan W, Wang Y, Tan W, Gao J. 2011. Signal peptide 754 
replacements enhance expression and secretion of hepatitis C virus envelope 755 
glycoproteins. Acta Biochim Biophys Sin (Shanghai) 43:96-102. 756 
59. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel AH, Bukh J, 757 
Foung SK. 2013. Cooperativity in virus neutralization by human monoclonal antibodies 758 
to two adjacent regions located at the amino terminus of hepatitis C virus E2 759 
glycoprotein. J Virol 87:37-51. 760 
60. Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK. 2011. Mapping a 761 
region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies 762 
and a core CD81-binding region that does not tolerate neutralization escape mutations. J 763 
Virol 85:10451-63. 764 
61. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, 765 
Foung SK. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus 766 




62. Andrianov AK, Svirkin YY, LeGolvan MP. 2004. Synthesis and biologically relevant 769 
properties of polyphosphazene polyacids. Biomacromolecules 5:1999-2006. 770 
63. Andrianov AK, Marin A, Fuerst TR. 2016. Molecular-Level Interactions of 771 
Polyphosphazene Immunoadjuvants and Their Potential Role in Antigen Presentation and 772 
Cell Stimulation. Biomacromolecules 17:3732-3742. 773 
64. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, 774 
Burton DR, Ward AB, Wilson IA, Law M. 2013. Hepatitis C virus E2 envelope 775 
glycoprotein core structure. Science 342:1090-4. 776 
65. Kortemme T, Kim DE, Baker D. 2004. Computational alanine scanning of protein-777 
protein interfaces. Sci STKE 2004:pl2. 778 
66. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel 779 
AH. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the 780 
hepatitis C virus E2 envelope glycoprotein. J Virol 79:11095-104. 781 
 782 
 783 
  784 
 
 32 
Figure Legends 785 
 786 
Figure 1. Structure-based design of E2 to stabilize and mask epitopes. A) Design of the E2 front 787 
layer. (top) Antigenic domain B-D supersite (green; also referred to as antigenic region 3) is 788 
highlighted on the E2 core X-ray structure (64), along with antigenic domain E (blue), and 789 
modeled N-glycans shown as orange sticks. Ramachandran plot analysis for proline-like 790 
backbone conformation (middle) and structural modeling of proline substitution structural and 791 
energetic effects (bottom) were performed using RosettaDesign and the HC84.26.5D-AS434 792 
epitope complex structure (31). HC84.26.5D HMAb is shown as wheat and light blue surface, 793 
epitope is green with selected mutant residue (H445P) shown as sticks. B) Design of the E2 back 794 
layer. (top) Antigenic domain A (red) was targeted for design and is shown on the E2 core 795 
structure, and antigenic domain C and modeled N-glycans are shown in cyan and orange sticks, 796 
respectively. (middle) Computational N-glycan scanning of antigenic domain A residues was 797 
performed to identify substitutions to mask its surface with designed NxS and NxT sequons. 798 
(bottom) Modeling of sequon mutants was performed in Rosetta (65), followed by modeling of 799 
N-glycan structures in the Glyprot Server (56). Modeled N-glycan design at Y632 (Y632N-800 
G634S) shown as green sticks, with E2 core structure gray (based on H77C E2, PDB code 801 
4MWF), E2 antigenic domain A residues red, and modeled native E2 N-glycans light blue sticks.  802 
 803 
Figure 2.  Antigenic characterization of E2 designs using ELISA. Designs were cloned and 804 
expressed in the context of E1E2 as previously described (28) and tested for binding to a panel of 805 
HMAbs that target E2 antigenic domain A (CBH-4G, CBH-4B), B (HC-1), C (CBH-7), D 806 
(HC84.28, HC84.24, HC84.26), and E (HC33.1, HC33.4), at concentrations of 1 μg/ml, and 5 807 
μg/ml. Binding was tested to wild-type H77C E1E2, and compared with designs ΔHVR1 (E2 808 
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residues 384-407 deleted), ΔHVR1411 (E2 residues 384-410 deleted), H445P, F627NT (F627N-809 
V629T), R630NT (R630N-Y632T), K628NS (K628N-R630S), and Y632NS (Y632N-G634S). 810 
Asterisks denote designs that were tested in the context of ΔHVR1411 (E2 residues 384-410 811 
deleted) rather than full length E1E2.  812 
 813 
Figure 3. Antigenic characterization of sE2 designs H445P and Y632NS using biolayer 814 
interferometry (BLI). (A) Measured binding of broadly neutralizing monoclonal antibody 815 
HC84.26.WH.5DL to E2 design H445P compared to wild-type soluble E2 (sE2). (B) Measured 816 
binding of non-neutralizing monoclonal antibody CBH-4G to E2 design Y632NS (Y632N-817 
G634S) compared to wild-type soluble E2 (sE2). Steady-state binding curve fits are shown, 818 
which were used to determine binding dissociation constants (Kd) values. 819 
 820 
Figure 4. Immunized serum recognition of E2 and two E2 epitopes. A) Immunized sera were 821 
tested using ELISA for binding to soluble H77C E2 (sE2) and linear epitopes from antigenic 822 
domain E (AS412, aa 410-425) and antigenic domain D (AS434, aa 434-446). Serum binding 823 
was tested at successive three-fold dilutions starting at 1:60, and values are reported as endpoint 824 
titers. B) Binding of peptides to control monoclonal antibodies HC33.1 (59), AP33 (66), and 825 
HC84.26.WH.5DL (31). 826 
 827 
Figure 5. Serum binding competition with monoclonal antibodies. Serum inhibition of binding 828 
by biotinylated monoclonal antibodies at a concentration of 1 µg/ml was tested at the serum 829 
dilutions shown, using ELISA. The monoclonal antibodies tested for serum competition target 830 




Figure 6. Immunized serum binding to recombinant E1E2 and HCV pseudoparticles (HCVpp). 833 
Immunized sera were tested for binding to (A) H77C E1E2, and HCVpp representing (B) H77C, 834 
(C) UKNP1.18.1, and (D) J6 isolates using ELISA. Serum binding was tested at three-fold 835 
dilutions starting at 1:100, and values are reported as endpoint titers. Murine sera with binding 836 
levels lower than the endpoint OD value at the minimum dilution (1:100) have titers shown as 837 
50. Due to insufficient sera, endpoint titers are not available for one mouse in the sE2 group and 838 
one mouse in ΔHVR1 group (E1E2, H77C HCVpp, J6 HCVpp), as well as two mice in the sE2 839 
group and one mouse in the ΔHVR1-Y632NS group (UKNP1.18.1 HCVpp). P-values between 840 
group endpoint titer values were calculated using Kruskal-Wallis analysis of variance with 841 
Dunn’s multiple comparison test, and significant p-values between sE2 control and sE2 design 842 
groups are shown (*: p  0.05; ****: p  0.0001). 843 
 844 
Figure 7. Comparison of concentrated HCV pseudoparticle (HCVpp) binding of immunized 845 
mouse sera from sE2 wild-type and H445P immunization. A preparation enriched in H77C 846 
HCVpps was tested for binding to pooled murine sera from sE2 wild-type and H445P groups 847 
using ELISA, for sera from Day 42 and Day 56. Best-fit curves are shown and were used to 848 
calculate EC50 values. 849 
 850 
Figure 8. Binding of concentrated HCV pseudoparticles (HCVpps), pseudotyped with H77C 851 
E1E2, to monoclonal antibodies. Binding measurements were performed using ELISA with 852 
antibodies targeting E2 (HCV1, HC84.26.WH.5DL, AR3A), E1E2 (AR4A, AR5A) and a 853 




Figure 9. Serum neutralization of homologous (H77C) and heterologous HCVpp. Immunized 856 
murine serum neutralization was tested using HCV pseudoparticles (HCVpps) representing 857 
H77C as well as six heterologous isolates. Neutralization for four HCVpp representing isolates 858 
with resistant phenotypes are shown on the right, as indicated. Neutralization titers are 859 
represented as serum dilution levels required to reach 50% virus neutralization (ID50), calculated 860 
by curve fitting in Graphpad Prism software. Serum dilutions were performed as two-fold 861 
dilutions starting at 1:64, and minimum dilution levels (corresponding to 1:64) are indicated as 862 
dotted lines for reference. Murine sera with low (calculated ID50 < 10) or incalculable ID50 863 
values due to low or background levels of neutralization (observed only for some mice for J6 864 
HCVpp neutralization) have ID50 shown as 10. Due to insufficient sera, J6 neutralization 865 
measurements did not include two mice from group 1 (sE2) and one mouse from group 4 866 
(ΔHVR1). P-values between group ID50 values were calculated using Kruskal-Wallis analysis of 867 
variance with Dunn’s multiple comparison test, and significant p-values between sE2 control and 868 
sE2 design groups are shown (*: p  0.05; **: p  0.01). 869 
 870 
Figure 10. Analysis of correlations in immunogenicity and antigenicity measurements. (A) Pairs 871 
of datasets of serum HCVpp neutralization (IC50) and antigen binding (endpoint titer) 872 
measurements were tested for Pearson correlations on an individual mouse level (42 points per 873 
dataset), and top correlations between datasets are shown. Pearson correlations were calculated 874 
using log-transformed ID50 and endpoint titer values. (B) UKNP2.4.1 versus UKNP1.18.1 875 
serum neutralization (ID50), with best-fit line in red, and calculated correlation (r) and p-value 876 
(p) shown. (C) Correlations between antigen binding (Kd) and immunogenicity measurements for 877 
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corresponding antigen group (group geometric mean ID50 or endpoint titer) were calculated, and 878 
most significant correlations are shown. Pearson correlations were calculated using negated log-879 
transformed Kd and log-transformed titer values. (D) UKNP1.18.1 group serum neutralization 880 
(ID50) versus HC84.26.WH.5DL HMAb affinity (Kd), with best-fit line in red, and calculated 881 
correlation (r) and p-value (p) shown. The log-scale x-axis for HC84.26.WH.5DL Kd is shown 882 
with reversed scale, in accordance with the polarity of the calculated correlation. For (A) and 883 
(C), correlation p-values are shown above each bar (*: p  0.05; **: p  0.01, ***: p  0.001, 884 
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Table 1. Backbone structure and proline mutant analysis of antigenic domain D residues. 913 












437 Trp -73.66 -18.28 Yes No 0.5 
438 Leu -59.18 -59.67 Yes No 0.3 
439 Ala -59.14 -37.12 Yes Yes 0 
440 Gly -56.62 -26.31 Yes Yes 0.1 
441 Leu -68.3 -40.87 Yes Yes 2.1 
442 Phe -80.55 -40.18 Yes Yes 2.7 
443 Tyr -159.11 143.78 No Yes 2.5 
444 Gln -110.46 128.63 No Yes 2.2 
445 His -58.15 153.22 Yes Yes 0 
     
 914 
1
Values and proline backbone analysis were obtained from the Ramachandran plot analysis web 915 
server (https://zlab.umassmed.edu/bu/rama/)(54). Pre-Pro assessments correspond to pre-proline 916 
Ramachandran plot conformation for the backbone of the preceding residue. Unfavorable Pro or 917 
Pre-Pro conformations are noted with gray shaded cells. 918 
2
Predicted binding energy change for proline epitope mutant to the HC84.26.5D HMAb, based 919 
on the X-ray structure of the complex (PDB code 4Z0X) and computational mutagenesis in 920 
Rosetta (55). Predicted destabilizing values (> 0.5 in Rosetta energy units) are indicated with 921 
shaded cells. 922 
  923 
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627 Phe 62.7 
628 Lys 89.4 
629 Val 38.4 
630 Arg 60.4 
631 Met 14 
632 Tyr 62.3 
633 Val 1.5 
1
Accessible surface areas calculated using the X-ray structure of H77 E2 core (PDB code 925 
4MWF) and the naccess program (57) with default parameters. Values reflect relative side chain 926 





Table 3. Antigenic and biophysical characterization of E2 designs.  929 
 930 
   
  Antibody/Receptor Binding KD, nM
3
  
















HC84.1 HCV1 HC33.1 CD81 
sE2 wild-
type 
84.5 8.4 15 1.8 5.1 4.3 30 42 9.5 22 
H445P 83.1 14 15 1.1 4.6 0.4 31 70 8.0 23 
Y632NS 81.4 37 180 1.2 4.6 4.0 83 26 6.5 31 
ΔHVR1 84.5 5.8 20 1.5 7.0 3.1 60 42 7.9 15 
ΔHVR1-
H445P 
82.9 11 15 1.5 2.3 2.4 51 46 7.6 10 
ΔHVR1-
Y632NS 
80.0 7.7 140 1.8 9.0 2.2 110 50 6.7 140 




sE2 wild-type corresponds to residues 384-661 of H77C E2, and listed designs represent point 933 
mutants or truncations of that sequence. Y632NS is an abbreviation for the double mutant 934 
Y632N-G634S, and ΔHVR1 denotes deletion of most of the HVR1 sequence at the N-terminus 935 
of E2, with resultant construct containing residues 408-661. “Triple” denotes combination of 936 
ΔHVR1, H445P, and Y632NS designs. 937 
2
Tm values are in C and were measured by differential scanning calorimetry. 938 
3
Steady-state dissociation constant (KD) values were measured by Octet biolayer interferometry. 939 
Antibodies are classified by their mapping to antigenic domains A, B, D, and E on E2 (28). 940 
Values in bold denote KD changes more than 5-fold versus wild-type E2 for that antibody.  941 
 
 50 
Table 4. Percentage occupancy for engineered N-glycan at position 632, determined by mass 942 
spectrometry.  943 
Design % Glycosylation EndoF Efficiency 
Y632NS 51 96 
ΔHVR1-Y632NS 44 97 
Triple
1
 22 100 
1
Combination of ΔHVR1, H445P, and Y632NS.  944 
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% ID H77 
sE2 
% ID H77 
ΔHVR1 
H77 1a Moderate 22 100 100 
UKNP1.18.1 1b Resistant 3 79 82 
UKNP1.20.3 1b Moderate 32 79 82 
UKNP2.4.1 2a Resistant 1 72 74 
UKNP2.1.2 2i Moderate 23 70 73 
UKNP4.1.1 4a Resistant 2 71 75 
J6 2a Resistant 11 71 74 
 946 
1
Neutralization phenotype and neutralization resistance rank based on assessment of 78 HCVpp 947 
with a panel of monoclonal antibodies by Urbanowicz et al. (40).  948 
2
Percent identities reflect percent amino acid sequence identities with H77C sE2 (aa 384-661) 949 
and ΔHVR1 (aa 408-661). 950 
